Roderic Mk Dale

US Patent:

20020032164, Mar 14, 2002

Filed:

May 3, 2001

Appl. No.:

09/847654

Inventors:

Roderic Dale - Wilsonville OR, US
Steven Gatton - Lake Oswego OR, US
Amy Arrow - Bethel ME, US
Terry Thompson - West Linn OR, US

International Classification:

A61K048/00
A61K031/7068
A61K031/7076
A61K031/7024
A61K031/675

US Classification:

514/044000, 514/023000, 514/047000, 514/048000, 514/051000, 514/090000

Abstract:

The present invention provides protonated compounds having antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi.

US Patent:

20030045490, Mar 6, 2003

Filed:

Feb 19, 2002

Appl. No.:

10/076597

Inventors:

Roderic Dale - Wilsonville OR, US
Amy Arrow - Bethel ME, US
Terry Thompson - West Linn OR, US

Assignee:

Oligos Etc. Inc.

International Classification:

A61K048/00
A61K031/5377
A61K031/522
C07H021/04
C07D473/18
C07D413/14

US Classification:

514/044000, 514/234500, 514/263310, 536/023200, 544/081000, 544/244000, 544/268000

Abstract:

This patent describes the invention of a series of novel therapeutic oligonucleotides targeted at inhibiting expression of genes coding for Phosphodiesterase 4. They are useful as analytical tools in the study of individual PDE isoforms and in the therapeutic treatment of depression, thrombosis, cystic fibrosis, gastric lesions, pulmonary hypertension, glaucoma, multiple sclerosis, atopic dermatitis, asthma and other allergic disorders as well as other illnesses in which an increase of cyclic AMP or a decrease in phosphodiesterase levels is useful.

US Patent:

20030083477, May 1, 2003

Filed:

Dec 15, 1998

Appl. No.:

09/211794

Inventors:

AMY ARROW - BETHEL ME, US
RODERIC M.K. DALE - WILSONVILLE OR, US
TOD MITCHELL WOOLF - NATICK MA, US

Assignee:

FOLEY & LARDNER

International Classification:

C07H021/04

US Classification:

536/023100

Abstract:

The invention provides a class of oligonucleotide that is optimized to target a specific RNA for RNAse H degradation and to be itself resistant to degradation within in plasma and within eukaryotic, especially mammalian cells. The oligonucleotides of the invention contain no naturally occurring 5′→3′-linked nucleotides. Rather, the invention provides oligonucleotides having two types of nucleotides: 2′-deoxyphosphorothioate, which activate RNase H, and 2′-modified nucleotides, which do not. The linkages between the 2′-modified nucleotides can be phosphodiesters, phosphorothioate or P-ethoxyphosphodiester. Activation of RNAse H is accomplished by a contiguous, RNAse H-activating region, which contains between three and five 2′-deoxyphosphorothioate nucleotides to activate bacterial RNAse H and between five and ten 2′-deoxyphosphorothioate nucleotides to activate eukaryotic and, particularly, mammalian RNAse H. Protection from degradation is accomplished by making the 5′ and 3′ terminal bases highly nuclease resistant and, optionally, by placing a 3′ terminal blocking group.

US Patent:

20030180789, Sep 25, 2003

Filed:

May 12, 2003

Appl. No.:

10/435217

Inventors:

Roderic Dale - Wilsonville OR, US

International Classification:

C12Q001/68
C12M001/34

US Classification:

435/006000, 435/287200

Abstract:

The present invention provides arrays having associated modified oligonucleotides that selectively bind to DNA or RNA, methods of making such arrays, assays for using such arrays, and the like. In one embodiment, the arrays of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array of the invention exhibit substantial resistance to nuclease degradation.

US Patent:

20030207834, Nov 6, 2003

Filed:

Jul 10, 2002

Appl. No.:

10/191997

Inventors:

Roderic Dale - Wilsonville OR, US
Amy Arrow - Bethel ME, US
Terry Thompson - Wilsonville OR, US

International Classification:

A61K048/00
A61K007/06
A61K007/11

US Classification:

514/044000, 424/070130

Abstract:

The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.

US Patent:

20040121352, Jun 24, 2004

Filed:

Apr 17, 2003

Appl. No.:

10/417350

Inventors:

Roderic Dale - Wilsonville OR, US

Assignee:

Oligos Etc. Inc.

International Classification:

C12Q001/68
C12M001/34

US Classification:

435/006000, 435/287200

Abstract:

The present invention provides arrays having associated modified oligonucleotides that selectively bind to DNA or RNA, methods of making such arrays, assays for using such arrays, and the like. In one embodiment, the arrays of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array of the invention exhibit substantial resistance to nuclease degradation.

US Patent:

20050025815, Feb 3, 2005

Filed:

Aug 21, 2003

Appl. No.:

10/644969

Inventors:

Roderic Dale - Wilsonville OR, US
Steven Gatton - Lake Oswego OR, US
Amy Arrow - Bethel ME, US

International Classification:

A61K048/00
A61K009/70

US Classification:

424445000, 514044000, 514047000, 514049000

Abstract:

The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule. The nucleic acids used in the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about 1, more preferably less than pH 4.5 to about 1, and even more preferably less than pH 2 to about 1.

US Patent:

20050107344, May 19, 2005

Filed:

Sep 8, 2004

Appl. No.:

10/937094

Inventors:

Roderic Dale - Wilsonville OR, US
Steven Gatton - Lake Oswego OR, US
Amy Arrow - Bethel ME, US
Terry Thompson - West Linn OR, US

International Classification:

A61K031/66

US Classification:

514102000

Abstract:

The present invention provides protonated compounds having antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi.